Antioxidant, Antimicrobial and Formulation of Borage (Borago officinalis) Seeds Oil and Leaves Extracts as Microemulsion

Aims: This study aims to investigate antioxidant and antibacterial activities of borage (seeds and leaves) extracts, and to prepare different topical microemulsion formulations using borage oil. Study Design: Borage seeds and leaves were collected from Hebron -Palestine, then the borage leaves and seeds were prepared for extraction and then extracted with Soxhlet using ethanol. The antimicrobial and antioxidant activity of the extracts were studied, and then Ternary Phase Diagram was constructed using the borage extracts (from seeds and leaves). Methodology: The seeds were cultivated upon their ripening season in April of 2016 from the Halhul mountains in Hebron/Palestine. Soxhlet method was used to extract borage seeds and leaves oil by using ethanol 95%. A ternary phase diagram was constructed by determining appropriate nonionic surfactant to assess the ability for microemulsion formulation and durability of each system. Tween 80 was found to be more suitable to solubilize each of borage seeds and leaves extracts compared with Tween 20 due to its prominent hydrophobic properties. The antibacterial activity was evaluated for both borage seeds and leaves extracts using a well diffusion method against Staphyloococcus aureus, Escherichia coli, &Candida albicans. Results: Results showed that the seeds extract has inhibition zone (12 mm) against S. aureus (gram positive bacteria) higher than inhibition zone that leaves extracts exhibited (7.5mm), but no significant effects observed for both extracts against E. coli and C. albicans. In addition, antibacterial activity for microemulsions formulation was measured against S. aureus, E. coli, and C. albicans. Results showed that there is minor activity against S. aureus when compared to PenicillinG and the pure seed oil or leaves extract. In contrast no activity was reported against E. coli and C. albicans. The antioxidant activity was further indicated by the quiet good ability to reduce the FRAP reagent for both extracts with the indication of higher seeds extract activity. This variation is explained by the higher seeds extract content of polyphenol, tocopherol and vitamin C than leaves extract. Conclusion: Borage seeds and leaves were extracted, and the extracts were showed antimicrobial and antioxidant activity and showed that they can be used in microemulsion using ternary phase diagram.

The effect of Borago officinalis on the signaling pathway of the NLRP3 inflammasome complex, TLR4 and some inflammatory cytokines in type II diabetic patients with acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a life-threatening condition in which the lungs become severely inflamed, causing the alveoli to constrict or fill with fluid, which prevents the lungs from functioning properly. This disease becomes more dangerous when it occurs in patients with diabetes. Because of the clinical condition of these patients, it is not possible to treat them with usual medicines. One of the best options for treating these people is to use herbs. Borage (Borago officinalis) is a medicinal herb that, in addition to its anti-inflammatory properties, is also able to control blood sugar. Therefore, in the current study, the effect of borage oil was considered on the signaling pathway of the NLRP3 inflammasome complex, TLR4, and serum levels of inflammatory cytokines (IL-1? and IL-18) in type II diabetic patients with ARDS. For this purpose, 25 diabetic type II patients with ARDS were divided into three groups by ARDS Berlin Definition. Then, after providing the demographic and clinical characteristics of the patients, they were treated with 30 mg/day borage oil for seven days. The expression of NLRP3 and TLR4 genes (by Real-time PCR technique) and serum levels of IL-1? and IL-18 (by ELISA test) were evaluated before and after treatment with borage oil through blood samples taken from patients. The results showed that serum levels of inflammatory cytokines (IL-1? and IL-18), NLRP3 gene, and TLR4 gene were significantly decreased in diabetic type II patients with mild ARDS by treating with borage oil. IL-1? serum level and TLR4 were significantly decreased in diabetic type II patients with moderate ARDS. But there was not any significant decrease or increase in IL-1?, IL-18, NLRP3 gene, and TLR4 gene in diabetic type II patients with severe ARDS after 7 days of treatment with borage oil. According to the obtained results, borage oil can act as a double-edged blade. Thus, in the early and middle stages of ARDS, borage oil can be effective in reducing the inflammasome pathway of inflammation and also reduce blood sugar levels in these diabetic patients. But in the severe stage of ARDS, it not only does not help to treat the ARDS; it also increases systolic and diastolic blood pressure in diabetic patients.

Health-Promoting Properties of Borage Seed Oil Fractionated by Supercritical Carbon Dioxide Extraction

Borage (Borago officinalis L.) seed oil is an important source of γ–linolenic acid, which is normally used as a treatment against different pathologies. Since the fractionation of this interesting seed oil has many environmental, economic and biological benefits, two borage fractionation techniques after extraction with CO2 under supercritical conditions have been studied: precipitation in two cyclone separators and countercurrent extraction column. Both techniques have successfully collected free fatty acids in one fraction: (i) two separators set up in series obtained the highest concentration of free fatty acids in separator 2 at 90 bar/40 °C; (ii) when countercurrent extraction column was used, the acidity index of the raffinate stream was independent from the operating conditions (2.6 ± 0.5%). Furthermore, the composition of the fatty acids, as well as their antioxidant and cytotoxic activities, were determined. The profile of the fatty acids obtained by either of these two methods remained unaltered, so that the crude oil exhibited improved antioxidant and cytotoxic properties. All the extracts obtained in the two cyclone separators at the same pressure/temperature conditions displayed high tumouricidal activity against HL 60 promyelocytic leukaemia cells, even if the extracts at 50% concentration from separator 2 presented a lower inhibitory activity (IC50). The extracts from separator 2 at 90 bar/40 °C exhibited the highest anti-proliferative activity at low doses (IC50 of 0.3 μL/mL for the trypan blue exclusion test). To reach the lethal dose—IC50—with the product obtained through countercurrent column fractionation, a concentration of 2 μL/mL of crude borage oil raffinate was required.

Phenolic profiles and antioxidant activities of Saskatchewan (Canada) bred haskap (Lonicera caerulea) berries

Phenolic extracts from five Saskatoon, Saskatchewan, bred and grown haskap berry varieties (Aurora, Blizzard, Honey Bee, Indigo Gem, and Tundra) were characterized via liquid chromatography with photodiode array detection (HPLC-PDA) and mass spectrometry (HPLC-MS/MS). Tundra had the highest phenolic content (727.0 mg/100 g FW) while Indigo Gem had the highest anthocyanin content (447.8 mg/100 g FW). HPLC-MS/MS identified two previously unreported anthocyanins (Tundra variety): delphinidin-sambubioside and a peonidin-pentoside. Fruit extracts were fractionated to produce an anthocyanin rich (40% ethanol) and flavanol/flavonol rich (100% ethanol) fraction. This process affords the ability to isolate/concentrate specific subclasses for nutraceutical applications. High in vitro radical scavenging was observed for all haskap phenolic extracts. An extract from the Tundra variety delayed borage oil oxidation more effectively than commercial antioxidants (BHT and Rosamox). These results show the high phenolic content of these haskaps along with their capacity for radical scavenging/delaying lipid oxidation, indicating potential commercial value.

Borage Oil Intake by Overweight Young Adults: No Effect on Metabolic Rate; Beneficial Effects on Plasma Triglyceride and HDL Cholesterol Readings

Some research has raised the possibility that gamma linolenic acid (GLA) can increase resting metabolic rate (RMR), which can help with weight control. However, in overweight young adults with a...

Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells

Combining more than one anticancer agent in a nanocarrier is beneficial in producing a formula with a low dose and limited adverse side effects. The current study aimed to formulate docetaxel (DTX) and thymoquinone (TQ) in borage oil-based nanoemulsion (B-NE) and evaluate its potential in impeding the growth of breast cancer cells. The formulated B-NE and the combination (DTX + TQ) B-NE were prepared by the ultra-sonication method and physically characterized by the dynamic light scattering techniques. The cytotoxicity analyses of (DTX + TQ) B-NE in MCF-7 and MDA-MB-231 cells were evaluated in vitro by using the SRB assay. Cell death mechanisms were investigated in terms of apoptosis and autophagy pathways by flow cytometry. The optimum mean droplet sizes formulated for blank B-NE and the (DTX + TQ) B-NE were 56.04 ± 4.00 nm and 235.00 ± 10.00 nm, respectively. The determined values of the half-maximal inhibitory concentration (IC50) of mixing one-half amounts of DTX and TQ in B-NE were 1.15 ± 0.097 µM and 0.47 ± 0.091 µM in MCF-7 and MDA-MB-231 cells, respectively, which were similar to the IC50 values of the full amount of free DTX in both tested cell lines. The treatment with (DTX + TQ) B-NE resulted in a synergistic effect on both tested cells. (DTX + TQ) B-NE induced apoptosis that was integrated with the stimulation of autophagy. The produced formulation enhances the DTX efficacy against human breast cancer cells by reducing its effective dose, and thus it could have the potential to minimize the associated toxicity.

Prospective clinical trial examining the impact of genetic variation in FADS1 on the metabolism of linoleic acid– and ɣ-linolenic acid–containing botanical oils

ABSTRACT Background Unexplained heterogeneity in clinical trials has resulted in questions regarding the effectiveness of ɣ-linolenic acid (GLA)-containing botanical oil supplements. This heterogeneity may be explained by genetic variation within the fatty acid desaturase (FADS) gene cluster that is associated with circulating and tissue concentrations of arachidonic acid (ARA) and dihomo-ɣ-linolenic acid (DGLA), both of which may be synthesized from GLA and result in proinflammatory and anti-inflammatory metabolites, respectively. Objectives The objective of this study was to prospectively compare the capacity of a non-Hispanic white cohort, stratified by FADS genotype at the key single-nucleotide polymorphism (SNP) rs174537, to metabolize 18-carbon omega-6 (n-6) PUFAs in borage oil (BO) and soybean oil (SO) to GLA, DGLA, and ARA. Methods Healthy adults (n = 64) participated in a randomized, double-blind, crossover intervention. Individuals received encapsulated BO (Borago officinalis L.; 37% LA and 23% GLA) or SO [Glycine max (L.) Merr.; 50% LA and 0% GLA] for 4 wk, followed by an 8-wk washout period, before consuming the opposite oil for 4 wk. Serum lipids and markers of inflammation (C-reactive protein) were assessed for both oil types at baseline and during weeks 2 and 4 of the intervention. Results SO supplementation failed to alter circulating concentrations of any n-6 long-chain PUFAs. In contrast, a modest daily dose of BO elevated serum concentrations of GLA and DGLA in an rs174537 genotype–dependent manner. In particular, DGLA increased by 57% (95% CI: 0.38, 0.79) in GG genotype individuals, but by 141% (95% CI: 1.03, 2.85) in TT individuals. For ARA, baseline concentrations varied substantially by genotype and increased modestly with BO supplementation, suggesting a key role for FADS variation in the balance of DGLA and ARA. Conclusions The results of this study clearly suggest that personalized and population-based approaches considering FADS genetic variation may be necessary to optimize the design of future clinical studies with GLA-containing oils. This trial was registered at clinicaltrials.gov as NCT02337231.